miR-145 suppresses osteogenic differentiation by targeting Sp7  by Jia, Jie et al.
FEBS Letters 587 (2013) 3027–3031journal homepage: www.FEBSLetters .orgmiR-145 suppresses osteogenic differentiation by targeting Sp70014-5793/$36.00  2013 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.
http://dx.doi.org/10.1016/j.febslet.2013.07.030
⇑ Corresponding author. Fax: +86 02785726114.
E-mail address: yongliu027@163.com (Y. Liu).Jie Jia, Qing Tian, Song Ling, Yong Liu ⇑, Shuhua Yang, Zengwu Shao
Department of Orthopedics, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430022, China
a r t i c l e i n f o a b s t r a c tArticle history:
Received 26 June 2013
Revised 11 July 2013
Accepted 11 July 2013
Available online 22 July 2013





Sp7Osteogenesis depends on a coordinated network of transcription factors including Sp7. Emerging
evidence indicates that microRNAs (miRNAs) act as pivotal regulators in various biological processes
including osteoblast proliferation and differentiation. Here, we investigated the effect of miR-145
on osteogenic differentiation. miR-145 was decreased during osteogenic differentiation, which
could suppress the osteogenic differentiation of C2C12 and MC3T3-E1 cells conﬁrmed by gain- and
loss-of-function experiments. Moreover, bioinformatic analysis combined with luciferase reporter
assay, and Western blot validated that miR-145 negatively regulated Sp7 expression. Inhibition of
Sp7 showed similar effect with miR-145 on osteogenic differentiation, whereas overexpression of
Sp7 attenuated this effect. Collectively, these data indicate that miR-145 is a novel regulator of
Sp7, and it suppresses the osteogenic differentiation of C2C12 and MC3T3-E1 cells.
 2013 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Skeletal development and homeostasis depend on the activity
of osteoblasts derived from mesenchymal stem cells. In addition,
bone development is constantly remodeled throughout life re-
quired rigid control of a variety of gene expression and repression
in response to physiological signals. Cohorts of tissue-speciﬁc tran-
scription factors mediate the expression of genes required for
osteoblast differentiation [1]. Three osteoblast-speciﬁc or highly
expressed transcription factors, Runt-related transcription factor
2 (RUNX2), Sp7 (also named as Osterix), and activating transcrip-
tion factor 4 (ATF4) act sequentially to regulate the differentiation
from an osteochondral progenitor into a fully differentiated and
functional osteoblast [2–4]. Especially, Sp7-null mice could not
form mature osteoblasts [5].
MicroRNAs (miRNAs) are a large family of small non-coding
(18–25 nucleotides) single-stranded RNAs, which mediate gene
suppression by binding to the 30 untranslated regions (30 UTRs)
of target mRNAs via either promoting degradation of target mRNAs
or inhibiting the translation [6]. MiRNAs play essential roles in di-
verse biological processes, including cell proliferation, differentia-
tion, apoptosis, and tumor oncogenesis [7–9]. Recently,
numerous studies have revealed that miRNAs play critical roles
in osteoblast differentiation. For example, miR-34s was reported
to inhibit osteoblast differentiation by targeting Special AT-richsequence-binding protein 2 (SATB2) [10]. MiR-100 suppressed
osteoblast differentiation by inhibiting bone morphogenetic pro-
tein receptor type II (BMPR2) [11]. MiR-133 and miR-135 function-
ally inhibit osteoprogenitor differentiation by abolishing Runx2
and SMAD family member 5 (Smad5) pathways which contributed
to bone formation synergistically [12]. Sp7 has been recently iden-
tiﬁed as a key regulator of osteoblast differentiation, it was re-
ported to be regulated by miR-93, miR-125b, miR-214, and miR-
637 [13–16]. However, miRNAs that regulate Sp7 expression still
require further investigation.
In this study, we characterized miR-145, a novel down-regu-
lated miRNA [17], and investigated its effects on osteoblast differ-
entiation. We identiﬁed Sp7 as its target, proposing a regulatory
mechanism in which miR-145/Sp7 controls osteoblast differentia-
tion. Our data shed new light on the roles of miRNAs in osteoblast
differentiation.
2. Materials and methods
2.1. Reagents, antibodies, plasmids
Recombinant bone morphogenetic protein 2 (BMP2) was pur-
chased from Invitrogen (CA, USA), Sp7-speciﬁc antibody was pur-
chased from Abcam (Cambridge, UK), and anti-GAPDH antibody
was purchased from Abcam. MiR-145 mimic/inhibitor and non-
speciﬁc control were obtained from RiboBio (Guangzhou, China).
Sp7 siRNA was purchased from Santa Cruz (CA, USA). Sp7-pcDNA3
plasmid was kindly provided by Prof. K. Watanabe. Lipofectamine
2000 was purchased from Invitrogen.
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C2C12 and MC3T3-E1 cells were obtained from ATCC. C2C12 cells
were maintained in DMEM supplemented with 15% FBS, 100 lg/ml
streptomycin, and 100 U/ml penicillin. MC3T3-E1 cells were main-
tained in a-modiﬁed Eagle’s medium supplemented with 10% FBS.
Cultured cells were incubated in a humid chamber containing 5%
CO2 at 37 C.
2.3. RNA isolation and quantitative real-time PCR
Total RNA was isolated with TRIzol reagent (Invitrogen, CA,
USA) according to the manufacturer’s protocol. cDNA was synthe-
sized from 1 lg total RNA using a Reverse Transcription Kit (TOY-
OBO, Tokyo, Japan) according to the manufacturer’s instruction.
Quantitative real-time PCR (qRT-PCR) was carried out using an
ABI Stepone plus Real-Time PCR System. The following primers
were used: GAPDH, forward: 50-ACCACAGTCCATGCCATCAC-30,
reverse: 50-TCCACCCTGTTGCTGTA-30; alkaline phosphatase (ALP),
forward: 50-GACAAGAAGCCCTTCACTGC-30, reverse: 50-AGA-
CTGCGCCTGGTAGTTGT-30; collagen type I (COL1A1), forward:
50-GAGAGCATGACCGATGGATT-30, reverse: 5-ATGTAGGC-
CACGCTGTTCTT-30; osteocalcin (OC), forward: 50-TGCTTGTGAC-
GAGCTATCAG-30, reverse: 50-GAGGACAG GGAGGATCAAGT-30;
Sp7, forward: 50-AGCGACCACTTGAGCAAACAT-30, reverse:
50-GCGGCTGATTGGCTTCTTCT-30. MicroRNA was extracted with
All-in-One microRNA extraction kit from GeneCopoeia (MD, USA).
Primers for miR-145 and the endogenous control U6 were
purchased from GeneCopoeia.
2.4. Western blot
Cells were lysed in RIPA buffer plus protease inhibitors (Roche,
IN, USA). Equal amount of proteins were loaded, and separated on
10% SDS–PAGE and then transferred to a PVDF membrane (Milli-
pore, MA, USA), blocked by incubation with 3% fat-free milk in
TBS buffer (150 mM NaCl, 50 mM Tris–HCl, pH 7.6) at 25 C for
1 h. The membranes were incubated with primary antibodies at
4 C overnight, and then were incubated with horseradish perox-
ide-conjugated secondary antibodies at 25 C for 1 h. The blots
were developed with ECL reagent (Pierce, IL, USA).
2.5. Alkaline phosphatase and Alizarin Red stainings
C2C12 cells seeded in 12-well plate were transfected with miR-
145 inhibitor or the control using Lipofectamine 2000. 30 h after
transfection, the cells were treated with BMP2 (5 ng/ml) for 4 d,
and were ﬁxed in 10% paraformaldehyde for 10 min at 25 C. The
cells were stained using 300 lg/ml BCIP/NBT buffer (Thermo, IL,
USA) for 20 min at 25 C. ALP-positive cells were stained blue/pur-
ple. For Alizarin Red staining, cells were stained with 2% Alizarin
Red (pH 7.2) for 15 min. Orange and red bodies were identiﬁed
as calcium nodules.
2.6. Luciferase assays
The 30 UTR of Sp7 was ampliﬁed using the following primers:
forward: 50-CCCTCGAGATGATGACGGGTCAGGTA-30, reverse: 50-
TTGCGGCCGCCCATTCTTCAGGAGGTGC-30. The sequence was
inserted into psiCHECK2 within XhoI and NotI restriction sites.
Mutation in the miR-145 binding-sites module of Sp7 was intro-
duced by whole-plasmid ampliﬁcation in the seed region of miR-
145 (NEB, Ipswich, Canada). C2C12 cells were co-transfected with
0.5 lg of the reporter vector (psiCHECK-2, psiCHECK-2-Sp7-WT-
30 UTR or psiCHECK-2-Sp7-WT-30 UTR) and 1 lg of miR-145
expression plasmid or the control vector. 48 h after transfection,cells were harvested and luciferase activity was detected using a
dual-luciferase reporter assay system (Promega, WI, USA).
2.7. Statistical analysis
Data are showed as mean ± S.D. Comparisons between groups
were analyzed via Student t test using SPSS 16.0. Statistical signif-
icance was deﬁned as P value <0.05.
3. Results
3.1. miR-145 was decreased during osteogenic differentiation
We ﬁrstly examined the changes of miR-145 expression during
osteogenic differentiation using qRT-PCR. C2C12 and MC3T3-E1
cells were used as a cell model, and osteogenic differentiation
was induced [18]. To induce the differentiation of C2C12 cells, the
mediumwasreplaced with DMEMwithout serum, and treated with
2 nM BMP2. To induce the differentiation of MC3T3-E1 cells, the
medium was replaced with a-modiﬁed Eagle’s medium containing
10% FBS, 5 mM b-glycerophosphate, and 50 lM ascorbic acid. Sev-
eral osteogenic factors, such as ALP, OC, and COL1A1 were used as
phenotypic markers of osteogenic differentiation. As shown in
Fig. 1A, there was a remarkable increase in ALP, OC, and COL1A1
mRNAs in C2C12 cells following the BMP2 treatment, and similar
results were observed in MC3T3-E1 cells (Fig. 1B), suggesting the
successful induction of osteogenic differentiation. MiR-145 was
remarkably decreased compared to the non-induced cells during
osteogenic differentiation (Fig. 1C). These data suggest that miR-
145 might play a role during osteogenic differentiation.
3.2. miR-145 suppressed osteogenic differentiation
We further investigated the role of miR-145 on osteogenic dif-
ferentiation by gain- and loss- of function experiments. C2C12 cells
were transfected with miR-145 inhibitor or the control. 36 h after
transfection, cells were incubated without serum for 24 h, and
expression of ALP, OC, and COL1A1 was detected using qRT-PCR.
All of the osteogenic differentiation markers measured were mark-
edly increased following transfection of the miR-145 inhibitor
(Fig. 2A). In contrast, C2C12 cells transfected with miR-145 mimic
showed decreased expression of osteogenic differentiation mark-
ers compared with those transfected with the control (Fig. 2B).
Similarly, at 6 d of differentiation, ALP staining showed a signiﬁ-
cant lessened difference in miR-145 group compared with the con-
trol group, whereas, after inhibition of miR-145, the outcome was
totally inversed (Fig. 2C upper). The Alizarin Red staining (ARS)
(Fig. 2C lower) at 15 d showed the similar tendency at the matrix
mineralization level. Efﬁciency of mi-145 mimic/inhibitor was
determined by qRT-PCR (Fig. 2D). These results indicate that
miR-145 could suppress osteogenic differentiation.
3.3. miR-145 inhibited Sp7 expression
miRNA target analysis tools TargetScan 6.2 and microrna.org
were used to explore potential target of miR-145. Sp7 was pre-
dicted to be a target of miR-145 (Fig. 3A). To validate targeting of
Sp7 by miR-145, we performed luciferase activity assay. The wild
type Sp7 30 UTR luciferase reporter plasmid (WT) or the mutant
(Mut) was co-transfected with miR-145 mimic or the control into
C2C12 cells. The co-transfection of miR-145 with WT in C2C12 cells
showed signiﬁcant inhibited luciferase activity compared with the
control group, while Mut luciferase activity did not changed
(Fig. 3B). Overexpression of miR-145 in C2C12 cells signiﬁcantly
suppressed the protein level of Sp7, while inhibition of miR-145
Fig. 1. miR-145 was decreased during osteogenic differentiation. (A) C2C12 cells were treated with BMP2 (2 nM) or the control for 24 h. Expression of ALP, OC, and COL1A1
was determined by qRT-PCR. (B) MC3T3-E1 cells were treated with BMP2 (2 nM) or the control for 24 h. Expression of ALP, OC, and COL1A1 was determined by qRT-PCR.
GAPDH was used as the internal control. (C) The levels of miR-145 in BMP2-induced and non-induced (control) C2C12 and MC3T3-E1 cells were measured using qRT-PCR. U6
was used as the internal control. The data were from three independent experiments (n = 4). ⁄P < 0.05, ⁄⁄P < 0.01 compared with the control group.
Fig. 2. miR-145 suppressed osteogenic differentiation. (A) C2C12 cells were transfected with miR-145 inhibitor (100 nM) or the control for 48 h. Expression of ALP, OC, and
COL1A1 was determined by qRT-PCR. (B) C2C12 cells were transfected with miR-145 mimic (100 nM) or the control for 48 h. Expression of ALP, OC, and COL1A1 was
determined by qRT-PCR. GAPDHwas used as the internal control. (C) ALP staining (upper) at 6 d and Alizarin Red staining (lower) at 15 d showed ALP activity and calciﬁcation
of osteogenic differentiation after transfection with miR-145 mimic or miR-145 inhibitor compared with their separate negative control. (D) C2C12 cells were transfected with
miR-145 mimic/inhibitor (100 nM) or the control for 48 h. Expression of miR-145 was determined by qRT-PCR. U6 was used as the internal control. The data were from three
independent experiments (n = 4). ⁄P < 0.05, ⁄⁄P < 0.01 compared with the control group.
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that miR-145 could negatively regulate Sp7 expression.
3.4. miR-145 suppressed osteogenic differentiation by targeting Sp7
Since miR-145 could suppress osteogenic differentiation and in-
hibit Sp7 expression, we further explore whether inhibition of Sp7
by siRNA could also perform similar effect with miR-145 overex-
pression on osteogenic differentiation of C2C12 cells. Effect of Sp7
siRNA was conﬁrmed by qRT-PCR (Fig. 4A) and Western blot
(Fig. 4B). As expected, C2C12 cells transfected with Sp7 siRNA
showed similar effect C2C12 cells transfected with miR-145 mimic
as showed in Fig. 2B (Fig. 4C). Furthermore, co-transfection of miR-145 mimic with Sp7 overexpression plasmid could attenuate the
effect of miR-145 on osteogenic differentiation of C2C12 cells
(Fig. 4D). These results suggested that miR-145 suppressed osteo-
genic differentiation of C2C12 cells partially by inhibiting Sp7
expression.
4. Discussion
Bone homeostasis is balanced between bone formation and
bone absorption by osteoblasts and osteoclasts respectively [19].
A growing body of evidence has revealed that miRNAs play critical
roles in both normal biological processes and the pathogenesis of
human diseases by post-transcriptionally regulating gene
Fig. 3. miR-145 inhibited Sp7 expression. (A) Schematic diagram of miR-145 target site in the 30 UTR of Sp7 mRNA and its mutated version. (B) The reporter construct
containing WT 30 UTR or Mut 30 UTR was co-transfected with the miR-145 mimic or the control in C2C12 for 24 h, and luciferase activity assay was performed. Relative Renilla
luciferase activity was normalized to that of ﬁreﬂy luciferase. (C) C2C12 cells were transfected with miR-145 mimic/inhibitor or the respective control for 48 h. Western blot
was used to detect the protein level of Sp7. The data were from three independent experiments (n = 4). ⁄P < 0.05 compared with the control group.
Fig. 4. miR-145 suppressed osteogenic differentiation by targeting Sp7. (A) C2C12 cells were transfected with Sp7 siRNA or the control for 72 h. Expression of Sp7 was
determined by qRT-PCR. (B) C2C12 cells were transfected with Sp7 siRNA or the control for 72 h. Western blot was used to detect the protein level of Sp7. (C) C2C12 cells were
transfected with Sp7 siRNA or the control for 72 h. Expression of ALP, OC, and COL1A1 was determined by qRT-PCR. (D) C2C12 cells were co-transfected with miR-145 mimic
(100 nM) or the control with Sp7-pcDNA3 for 48 h. Expression of ALP, OC, and COL1A1 was determined by qRT-PCR. GAPDH was used as the internal control. The data were
from three independent experiments (n = 4). ⁄P < 0.05, ⁄⁄P < 0.01 compared with the control group; #P < 0.05 compared with miR-145 mimic transfected group.
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osteogenesis [21]. In the present study, we identiﬁed miR-145 as
a negative regulator of osteogenic differentiation. Our data
revealed that miR-145 was down-regulated during osteogenic
differentiation of C2C12 and MC3T3-E1 cells. Overexpression ofmiR-145 inhibited osteogenic differentiation, whereas inhibition
of miR-145 enhanced the osteogenic potential.
It has been reported that miR-145 was aberrantly expressed in
several tumors and served as a tumor suppressor, and it suppresses
cell growth and invasion by targeting a number of important genes
J. Jia et al. / FEBS Letters 587 (2013) 3027–3031 3031[22–24]. Here we found out a new role of miR-145 in the osteogen-
esis of C2C12 and MC3T3-E1 cells. To study the molecular mecha-
nism by which miR-145 regulates osteogenic differentiation,
Targetscan and microrna.org predicted that Sp7 might be a possi-
ble target with 6 nt consecutive match site complementary to
miR-145 in the 30 UTR of Sp7. We showed that miR-145 overex-
pression resulted in suppression of Sp7 at the protein level,
whereas functional inhibition of miR-145 led to elevation of Sp7,
strongly suggesting that Sp7 was regulated by miR-145. Mean-
while, dual luciferase reporter assay also identiﬁed Sp7 as a direct
target of miR-145. Sp7 supplement by Sp-pcDNA3, a Sp7 overex-
pression plasmid, could attenuate the effect of miR-145 on osteo-
genic differentiation, suggesting that miR-145 negatively
regulated osteogenic differentiation might by inhibiting Sp7.
C2C12, a typical pluripotent mesenchymal precursor cell, has the
potential to differentiate into osteoblasts, chondroblasts, and myo-
blasts [25,26]. BMP2 or other molecules direct the differentiation
of C2C12 cells into the osteoblast. Moreover, ALP, OC, and COL1A1
are typical osteoblast differentiation markers [18]. In this study,
we used C2C12 and MC3T3-E1cells to induce osteoblast differentia-
tion, and the successful induction was revealed by the dramatic
elevation of the osteoblast markers ALP, OC, and COL1A1. We
found that the expression of miR-145 was decreased in osteogenic
differentiation. Moreover, the transfection of miR-145 inhibitor led
to an elevation in osteoblast markers. These data suggest that miR-
145 might be involved in osteoblast differentiation negatively. Fur-
thermore, ALP staining and ARS assays determined that miR-145
negatively regulated osteogenic differentiation of C2C12 cells, sug-
gesting that miR-145 might act as a suppressor in osteogenic
differentiation.
Sp7 is a C2H2 zinc ﬁnger transcription factor that is essential for
proliferation, osteoblast differentiation, and bone formation. Sp7
regulates the expression of several osteogenic factors, including
ALP, OC, osteonectin, and osteopontin by binding to speciﬁc GC-
rich sequences [5]. Osx is speciﬁcally expressed in osteoblasts
and regulated by a number of miRNAs. Here, we demonstrated that
miR-145 negatively target Sp7 and suppressed osteogenic
differentiation.
In conclusion, our data indicate that miR-145 was a novel reg-
ulator of Sp7 and that it acted as a suppressor of osteogenic differ-
entiation. Our ﬁndings shed new light on the roles of miRNAs in
osteoblastdifferentiation.
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